Your browser doesn't support javascript.
loading
NLRP4 negatively regulates type I interferon response and influences the outcome in anti-programmed cell death protein (PD)-1/PD-ligand 1 therapy.
Wang, Hui; Xia, Liliang; Yao, Cheng-Cheng; Dong, Hui; Yang, Yi; Li, Chong; Ji, Wen-Xiang; Sun, Rui-Ming; Duan, Huang-Qi; Mengzhou, Wenli; Xia, Wei-Min; Wang, Shu-Jun; Ji, Ping; Li, Ziming; Jiao, Lei; Wang, Ying; Lu, Shun.
Afiliação
  • Wang H; Department of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
  • Xia L; Department of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
  • Yao CC; Department of Immunology and Microbiology, Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Dong H; Department of Immunology and Microbiology, Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Yang Y; Department of Gastroenterology, Shanghai Key Laboratory of Pancreatic Diseases, Shanghai General Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Li C; Department of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
  • Ji WX; Department of Oncology, Shanghai Medical College, Cancer Institute, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China.
  • Sun RM; Department of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
  • Duan HQ; Department of Immunology and Microbiology, Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Mengzhou W; Department of Urology, Xinhua Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Xia WM; Department of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
  • Wang SJ; Department of Urology, Xinhua Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Ji P; Department of Immunology and Microbiology, Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Li Z; Department of Immunology and Microbiology, Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Jiao L; Department of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
  • Wang Y; Department of High Content Pathology Center, Panovue Biological Technology Co., Ltd, Beijing, China.
  • Lu S; Department of Immunology and Microbiology, Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Cancer Sci ; 113(3): 838-851, 2022 Mar.
Article em En | MEDLINE | ID: mdl-34927309
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Limite: Animals / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Limite: Animals / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2022 Tipo de documento: Article